当前位置： SCI文献检索 > Journal of Pain Research期刊下所有文献 > Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study.

Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study.

Abstract：

Background:Previous studies have shown the efficacy of tapentadol (TP) for chronic cancer pain. We evaluated multiple effectiveness aspects of TP prolonged release on moderate-severe cancer-related pain, neuropathic pain (NeP), patient satisfaction, and quality of life. Methods:An observational prospective study was conducted on 80 cancer patients. Opioid-naïve patients received a starting dose of prolonged-release TP 50 mg twice daily, and opioid-experienced patients were switched to TP, not to exceed 500 mg/day. Treatment response was evaluated at 3, 6, 30-40, and 60-70 days through response rate, numeric rating-scale scoring, survival analysis (time to event for response), pain-intensity difference, TP escalation-index percentage, and effects on NeP. The drug-sparing effect on concomitant therapies was evaluated. Results:Seventy of 80 patients (88%) were responders to treatment (95% CI 78%-94%). Compared to T0, pain-intensity reductions were statistically significant for all intervals (P<0.01), with better results at T3/T4. NeP was significantly reduced at T4 (P<0.01). The probability of response was low at the initial stages and increased during the study. Pain-intensity differences decreased during the study, though without significance. Two patients (2.5%) left the study for TP-induced side effects. A significant improvement in quality of life was observed after 30-40 days (P<0.01). The majority of patients were "satisfied", "very satisfied", or "extremely satisfied" (T3-T4). Conclusion:TP was effective in terms of drug-sparing effect, response rate, TP escalation-index percentage, and NeP management. By comparing data from the survival analysis with the response rate and time to response (numeric rating scale from T0 to T4), we found that although TP induced a quick response, a longer period of therapy and higher doses were needed to improve the positive result.

journal_name

J Pain Res

journal_title

Journal of pain research

authors

Cascella M,Forte CA,Bimonte S,Esposito G,Romano C,Costanzo R,Morabito A,Cuomo A

doi

10.2147/JPR.S181079

subject

Has Abstract

pub_date

2018-12-24 00:00:00

pages

117-125

issn

1178-7090

pii

jpr-12-117

journal_volume

pub_type

杂志文章

在线工具

Multiple effectiveness aspects of tapentadol for moderate-severe cancer-pain treatment: an observational prospective study.